Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 3/20 | 0.40 |
| ▸ | DPP4 | P27487 | 4/20 | 0.39 |
| ▸ | PREP | P48147 | 1/20 | 0.39 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.39 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.39 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.39 |
| ▸ | NTRK1 | P04629 | 3/20 | 0.38 |
| ▸ | GPR119 | Q8TDV5 | 4/20 | 0.36 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.35 |
| ▸ | EPAS1 | Q99814 | 1/20 | 0.35 |
| ▸ | FAP | Q12884 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL430865 | 1.00 | AR (0.40) | ARDPP4PREPDPP8DPP9 | |
| SCHEMBL12688003 | 1.00 | AR (0.40) | ARDPP4PREPDPP8DPP9 | |
| SCHEMBL445864 | 1.00 | AR (0.40) | ARDPP4PREPDPP8DPP9 | |
| SCHEMBL12478221 | 0.89 | AR (0.40) | ARGPR119RIPK1EPAS1 | |
| SCHEMBL433026 | 0.89 | AR (0.40) | ARGPR119RIPK1EPAS1 | |
| SCHEMBL431625 | 0.89 | AR (0.40) | ARGPR119RIPK1EPAS1 | |
| SCHEMBL457104 | 0.89 | AR (0.40) | ARGPR119RIPK1EPAS1 | |
| SCHEMBL445752 | 0.89 | AR (0.40) | ARGPR119RIPK1EPAS1 | |
| SCHEMBL446078 | 0.83 | AR (0.36) | ARGPR119RIPK1EPAS1 | |
| SCHEMBL446079 | 0.83 | AR (0.36) | ARGPR119RIPK1EPAS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8637516-B2 | Compounds and compositions as TRK inhibitors | IRM LLC (BM) | 2014-01-28 | — | — | US | disclosed |
| US-20120065184-A1 | COMPOUNDS AND COMPOSITIONS AS TRK INHIBITORS | IRM LLC (BM) | 2012-03-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120065184-A1 | COMPOUNDS AND COMPOSITIONS AS TRK INHIBITORS | TNK2, CNKSR1, BMP2K | AR 747/4885DPP4 1728/4885PREP 4415/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.